In humans, a study using the AAV9 vector to deliver an artificial miRNA targeting the SOD1 gene in two patients with familial ALS found that it could safely inhibit SOD1 transcription, reduce polypeptide dipeptide levels, and maintain the functional stability for 18 months (47). This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.